Antiangiogenic therapy in lung cancer

Focus on vascular endothelial growth factor pathway

Grzegorz Korpanty, Elizabeth Smyth, Laura A. Sullivan, Rolf A. Brekken, Desmond N. Carney

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalExperimental Biology and Medicine
Volume235
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Vascular Endothelial Growth Factor A
Tumors
Lung Neoplasms
Growth Factor Receptors
Biological Therapy
Public Opinion
Cause of Death
Neoplasms
Therapeutics
Survival Rate

Keywords

  • Angiogenesis
  • Antiangiogenesis
  • Lung cancer
  • VEGF

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Antiangiogenic therapy in lung cancer : Focus on vascular endothelial growth factor pathway. / Korpanty, Grzegorz; Smyth, Elizabeth; Sullivan, Laura A.; Brekken, Rolf A.; Carney, Desmond N.

In: Experimental Biology and Medicine, Vol. 235, No. 1, 01.2010, p. 3-9.

Research output: Contribution to journalArticle

Korpanty, Grzegorz ; Smyth, Elizabeth ; Sullivan, Laura A. ; Brekken, Rolf A. ; Carney, Desmond N. / Antiangiogenic therapy in lung cancer : Focus on vascular endothelial growth factor pathway. In: Experimental Biology and Medicine. 2010 ; Vol. 235, No. 1. pp. 3-9.
@article{3ac103e8ffb14cd28b7e1db06b5a8887,
title = "Antiangiogenic therapy in lung cancer: Focus on vascular endothelial growth factor pathway",
abstract = "Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15{\%}. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.",
keywords = "Angiogenesis, Antiangiogenesis, Lung cancer, VEGF",
author = "Grzegorz Korpanty and Elizabeth Smyth and Sullivan, {Laura A.} and Brekken, {Rolf A.} and Carney, {Desmond N.}",
year = "2010",
month = "1",
doi = "10.1258/ebm.2009.009191",
language = "English (US)",
volume = "235",
pages = "3--9",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Antiangiogenic therapy in lung cancer

T2 - Focus on vascular endothelial growth factor pathway

AU - Korpanty, Grzegorz

AU - Smyth, Elizabeth

AU - Sullivan, Laura A.

AU - Brekken, Rolf A.

AU - Carney, Desmond N.

PY - 2010/1

Y1 - 2010/1

N2 - Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.

AB - Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.

KW - Angiogenesis

KW - Antiangiogenesis

KW - Lung cancer

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=76749101884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749101884&partnerID=8YFLogxK

U2 - 10.1258/ebm.2009.009191

DO - 10.1258/ebm.2009.009191

M3 - Article

VL - 235

SP - 3

EP - 9

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 1535-3702

IS - 1

ER -